HOLLYWOOD, FL--(Marketwire - May 27, 2009) - bioRASI, a full service, global Contract Research Organization (CRO), announced today that they will be participating in the MAGI 2009 Clinical Research Conference on May 31st - June 3rd. Dr. Boris Reznik, Chairman of bioRASI, will be a keynote speaker at the event's symposium titled, "Lessons Learned, Study Post Mortems." Leading the Symposium, Dr. Reznik will be discussing the issues of improving Clinical Research Processes through applying Deming's "Continues Improvement Process" (CIP).
"Too often, 'Lessons Learned' is reduced to trying to derive value from anecdotal review of the issues after the clinical trials are completed," Dr. Boris Reznik said. "At bioRASI, in order to consistently increase the quality of our work, we have been applying a method developed by the legendary W. Edwards Deming: 'Continues Improvement Process.' We not only believe that our approach produces significantly improved results, but we actually can measure them. The successful implementation of CIP at bioRASI was based upon making CIP a part of bioRASI's standard operating infrastructure: BPI 2008."
Through its Innovative and Generics divisions, bioRASI leverages its in-depth knowledge and global resources to provide a full range of services to its sponsors, including program management, regulatory strategy design and implementation, clinical development, analytical lab services, Part 11 compliant data management, data analysis and report writing.
bioRASI has leveraged its unique global access to strong PIs and special patient populations to optimize translational clinical development programs. Additionally, utilizing bioRASI's Phase I clinics and bioanalytical laboratories, bioRASI has a rich history of completing difficult to recruit and difficult to perform PK, BE and BA studies.
About bioRASI
bioRASI is a Full Service Global CRO that collaborates with the leading
biotech and pharmaceutical companies in the clinical development of novel
and generic therapeutics. Specializing in Innovative, ANDA and 505(b)(2)
NDA programs, bioRASI facilitates obtaining FDA approvals by delivering
high quality regulatory and clinical strategies, solutions and services,
while saving their clients critical time. bioRASI services include program
management, regulatory, clinical, data management and analysis, compliance
and audit. bioRASI leverages its access to world renowned researchers and
facilities in the U.S., Europe and Asia, to achieve unparalleled
scientific, clinical and business results at significantly lower costs.
bioRASI is headquartered in Hollywood, FL and has regional offices, labs,
and clinics across the globe.